Program
lorlatinib
Also written as “Lorlatinib”, “PF-06463922” and “Lorlatinib 50 mg”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Carcinoma · Renal Insufficiency, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 173 open or running | phase 4since Apr 22, 2020 | Oct 16, 2013 | Nov 30, 2028NCT06487078 |
| CStone Pharmaceuticals | 11 open or running | phase 2since Mar 17, 2022 | Mar 17, 2022 | none ahead |
| Hoffmann-La Roche | 11 open or running | phase 1since May 14, 2026 | May 14, 2026 | Aug 31, 2030phase 1 · NCT07617337 |
| Strata Oncology | 10 open or running | phase 2since Oct 1, 2021 | Oct 1, 2021 | none ahead |
Also a collaborator on its studies: Merck and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Oct 16, 2013.
- Jan 20, 2017Phase 3 study in Carcinoma, Non-Small-Cell LungPfizer · NCT03052608 · 296 enrolled · United States, Argentina, Australia and more
- May 17, 2017Phase 1 study in Carcinoma, Non-Small-Cell LungPfizer · NCT03184168 · 6 enrolled · United States
- May 18, 2018Phase 1 study in Renal InsufficiencyPfizer · NCT03542305 · 29 enrolled · United States
- Sep 24, 2018Phase 1 study in NeoplasmsPfizer · NCT03726333 · 1 enrolled · United States
- Feb 5, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungPfizer · NCT03909971 · 109 enrolled · China
- May 22, 2019Phase 1 study in AdultPfizer · NCT03961997 · 16 enrolled · Belgium
- Apr 22, 2020Phase 4 study in CarcinomaPfizer · NCT04362072 · 71 enrolled · United States, India, Italy and more
- Aug 21, 2020Phase 4 study in Advanced Non-Small Cell Lung CancerPfizer · NCT04541706 · 100 enrolled · India
- Oct 1, 2021Strata Oncology's first study: phase 2 study in NeoplasmsNew to Strata OncologyStrata Oncology · NCT05097599 · 11 enrolled · United States
- Nov 22, 2021Phase 4 study in Carcinoma, Non-Small-Cell LungPfizer · NCT05144997 · 76 enrolled · United States, China, France and more
- Jan 24, 2022Phase 1 study in Moderate Hepatic ImpairmentPfizer · NCT05224609 · 21 enrolled · United States
- Mar 17, 2022CStone Pharmaceuticals's first study: phase 2 study in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerNew to CStone PharmaceuticalsCStone Pharmaceuticals · NCT05297890 · 70 enrolled · China
- Jun 5, 2024No phase study in ALK+ Non-Small-Cell Lung CarcinomaPfizer · NCT06487078 · 90 planned · France
- May 14, 2026Hoffmann-La Roche's first study: phase 1 study in ALK Positive Non-small Cell Lung CancerNew to Hoffmann-La RocheHoffmann-La Roche · NCT07617337 · 102 planned · United States, Japan
Ahead
- Nov 30, 2028Primary completion: no phase study in ALK+ Non-Small-Cell Lung CarcinomaPfizer · NCT06487078
- Oct 25, 2029Primary completion: phase 4 study in Carcinoma, Non-Small-Cell LungPfizer · NCT05144997
- Aug 31, 2030Primary completion: phase 1 study in ALK Positive Non-small Cell Lung CancerHoffmann-La Roche · NCT07617337
TargetBeta
“An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), ”NCIt, by rule
“ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 31 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07617337ALK Positive Non-small Cell Lung Cancer · United States, Japan | 1 | Recruiting | Hoffmann-La Roche | Aug 31, 2030 | 102 |
| NCT06487078ALK+ Non-Small-Cell Lung Carcinoma · France | – | Recruiting | Pfizer | Nov 30, 2028 | 90 |
| NCT05297890Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer · China | 2 | Active, not recruiting | CStone Pharmaceuticals | Dec 26, 2023 | 70 |
| NCT05224609Moderate Hepatic Impairment · United States | 1 | Completed | Pfizer | Aug 13, 2024 | 21 |
| NCT05144997Carcinoma, Non-Small-Cell Lung · United States, China, France and more | 4 | Active, not recruiting | Pfizer | Oct 25, 2029 | 76 |
| NCT05097599Neoplasms · United States | 2 | Terminated | Strata Oncology | Jun 12, 2024 | 11 |
| NCT04541706Advanced Non-Small Cell Lung Cancer · India | 4 | Completed | Pfizer | Jul 20, 2022 | 100 |
| NCT04362072Carcinoma · United States, India, Italy and more | 4 | Completed | Pfizer | May 29, 2024 | 71 |
| NCT03961997Adult · Belgium | 1 | Completed | Pfizer | Dec 9, 2019 | 16 |
| NCT03909971Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Pfizer | Aug 10, 2020 | 109 |
| NCT03726333Neoplasms · United States | 1 | Terminated | Pfizer | Jul 8, 2021 | 1 |
| NCT03542305Renal Insufficiency · United States | 1 | Completed | Pfizer | Feb 20, 2020 | 29 |
| NCT03184168Carcinoma, Non-Small-Cell Lung · United States | 1 | Completed | Pfizer | Aug 7, 2017 | 6 |
| NCT03052608Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Mar 20, 2020 | 296 |
| NCT02838264Healthy · Belgium | 1 | Completed | Pfizer | Mar 31, 2017 | 16 |
| NCT02804399Healthy · United States | 1 | Completed | Pfizer | Oct 2016 | 12 |
| NCT02584634Carcinoma, Non-Small-Cell Lung · United States, Australia, Japan and more | 2 | Terminated | Pfizer | Feb 2, 2021 | 43 |
| NCT02569554Healthy · Belgium | 1 | Completed | Pfizer | Apr 2016 | 27 |
| NCT02564562Healthy · United States | 1 | Completed | Pfizer | Nov 2015 | 6 |
| NCT01970865Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 2 | Completed | Pfizer | Mar 15, 2017 | 364 |
How it is read
Names in the registry
- “Lorlatinib”, 10 entries
- “PF-06463922”, 8 entries
- “lorlatinib”, 6 entries
- “Lorlatinib 50 mg”, 1 entry
- “Lorlatinib 75 mg”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Neoplasms, 2 studies
- Carcinoma, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.